OpenURL Connection Search

Select item for more details and to access through your institution.

First clinical trial of the selective cardiac myosin activator, CK-1827452, in Heart Failure: effect of dose and plasma concentration on systolic function
Published in:
2008
By:
- Cleland, J.G.F.;
- McMurray, J.J.;
- Lang, C.C.;
- Clarke, C.P.;
- Neyses, L.;
- Saikali, K.G.;
- Lee, J.H.;
- Goldman, J.;
- Teerlink, J.R.;
- Malik, F.I.
Publication type:
Abstract
First clinical trial of the selective cardiac myosin activator, CK-1827452, in Heart Failure: effect of dose and plasma concentration on systolic function
Published in:
2008
By:
- Cleland, J.G.F.;
- McMurray, J.J.;
- Lang, C.C.;
- Clarke, C.P.;
- Neyses, L.;
- Saikali, K.G.;
- Lee, J.H.;
- Goldman, J.;
- Teerlink, J.R.;
- Malik, F.I.
Publication type:
Abstract
486 Clinical composite endpoint classification of REVIVE II corresponds to all-cause mortality risk
Published in:
2007
By:
- Teerlink, J.R.;
- Delgado-Herrera, L.;
- Thakkar, R.;
- Huang, B.;
- Padley, R.J.
Publication type:
Abstract
477 Patient self-assessments of heart failure status using either categorical or continuous scales were highly correlated in REVIVE IandII
Published in:
2007
By:
- Teerlink, J.R.;
- Thakkar, R.;
- Salon, J.;
- Huang, B.;
- Padley, R.J.
Publication type:
Abstract
486 Clinical composite endpoint classification of REVIVE II corresponds to all-cause mortality risk
Published in:
2007
By:
- Teerlink, J.R.;
- Delgado-Herrera, L.;
- Thakkar, R.;
- Huang, B.;
- Padley, R.J.
Publication type:
Abstract
477 Patient self-assessments of heart failure status using either categorical or continuous scales were highly correlated in REVIVE IandII
Published in:
2007
By:
- Teerlink, J.R.;
- Thakkar, R.;
- Salon, J.;
- Huang, B.;
- Padley, R.J.
Publication type:
Abstract

Found: 6

First clinical trial of the selective cardiac myosin activator, CK-1827452, in Heart Failure: effect of dose and plasma concentration on systolic function

First clinical trial of the selective cardiac myosin activator, CK-1827452, in Heart Failure: effect of dose and plasma concentration on systolic function

486 Clinical composite endpoint classification of REVIVE II corresponds to all-cause mortality risk

477 Patient self-assessments of heart failure status using either categorical or continuous scales were highly correlated in REVIVE IandII

486 Clinical composite endpoint classification of REVIVE II corresponds to all-cause mortality risk

477 Patient self-assessments of heart failure status using either categorical or continuous scales were highly correlated in REVIVE IandII